Comparative Pharmacology
Head-to-head clinical analysis: KEFLET versus KEFLEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KEFLET versus KEFLEX.
KEFLET vs KEFLEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Keflet (warfarin) inhibits vitamin K epoxide reductase, preventing the recycling of vitamin K and thereby reducing the synthesis of clotting factors II, VII, IX, and X in the liver.
Cephalexin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
500 mg orally every 12 hours for 10-14 days; for uncomplicated UTI: 250 mg orally every 12 hours for 7 days.
250-500 mg orally every 6 hours; maximum 4 g/day.
None Documented
None Documented
0.5-1 hour; prolonged in renal impairment (up to 20-30 hours in ESRD).
0.5–1.2 hours in patients with normal renal function (CrCl >50 mL/min); prolonged to >20 hours in ESRD.
Renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal < 5%.
Primarily renal (90% or more unchanged via glomerular filtration and tubular secretion); small amounts biliary/fecal (<5%).
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic